✓Sep 8 session - Last update: Sep 8, 2026, 4:45 PM ET
⚡Material / Earnings✓High confidence
Source: daily_prices:fmp_change_percent
Changes History →Pre-market · Regular session opens 9:30 AM ET
Last update: Sep 8, 2026, 6:08 PM ETMarket closed·106 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓Sep 8 session - Last update: Sep 8, 2026, 4:45 PM ET
⚡Material / Earnings✓High confidence
What changed: TKO Group Holdings, Inc. (TKO) moved +5.53% from $185.09 to $195.32 on September 8, 2026, on volume 2.7x the 5-day average. News reports noted the stock dipped intraday to $186.01 amid ongoing investor caution about sports media rights valuations, but recovered sharply by day's end. The company declared a third-quarter cash dividend of $0.79 per share (ex-dividend date September 15, 2026) following strong Q2 earnings and raised full-year guidance in August.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
TKO earnings scheduled for November 4, 2026 (consensus EPS estimate $1.33) will test whether the raised full-year guidance remains on track.
✓Sep 8 session - Last update: Sep 8, 2026, 4:51 PM ET
⚡Material / Earnings✓High confidence
What changed: Twist Bioscience Corporation (TWST) moved +5.44% from $121.45 to $128.06 on 2026-09-08, driven by positive sentiment around AI-enabled drug discovery demand and recent financial strength. The move followed the company's fiscal Q3 2026 earnings beat, an upsized capital raise, and raised forward guidance, with analyst price-target revisions reinforcing confidence in its technology leadership and order growth trajectory.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
TWST earnings are scheduled for 2026-11-13 (consensus EPS estimate −$0.44); monitor whether the company sustains its recent beat streak and provides updated guidance.
✓Sep 8 session - Last update: Sep 8, 2026, 4:50 PM ET
⚡Material / Earnings✓High confidence
What changed: Scholar Rock Holding Corporation (SRRK) moved +6.16% from $54.09 to $57.42 on September 8, 2026, as investors anticipated the September 30, 2026 FDA decision date for its lead spinal muscular atrophy drug, apitegromab. The BLA was streamlined after removing a troubled manufacturing facility, keeping the review on schedule for the PDUFA action date. The company also recently secured FDA Fast Track and Orphan Drug designations for apitegromab in facioscapulohumeral muscular dystrophy.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
FDA PDUFA action date on September 30, 2026, for apitegromab BLA decision.
✓Sep 8 session - Last update: Sep 8, 2026, 4:48 PM ET
⚡Material / Earnings✓High confidence
What changed: Glaukos Corporation (GKOS) moved +5.50% from $175.39 to $185.04 on September 8, 2026. The move was driven by sustained commercial momentum in its flagship iDose TR interventional glaucoma product and early-stage Epioxa launch for corneal diseases, combined with Wall Street confidence following the company's Q2 earnings beat and raised full-year 2026 sales guidance to $680–$700 million (a 9% increase from prior guidance).
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Glaukos is scheduled to report Q3 2026 earnings on November 4, 2026 (date not yet confirmed); consensus EPS estimate is −$0.13.
✓Sep 8 session - Last update: Sep 8, 2026, 4:41 PM ET
🛡Material / Earnings✓High confidence
What changed: Cerebras Systems Inc. (CBRS) moved -7.95% from $217.03 to $199.77 on 2026-09-08. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor CBRS's Q3 2026 earnings report on 2026-09-22 for actual results versus the $-0.21 EPS consensus estimate and any forward guidance.
✓Sep 8 session - Last update: Sep 8, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Robinhood Markets, Inc. (HOOD) moved -6.18% from $125.07 to $117.34 on 2026-09-08. We checked news, earnings, analyst updates, filings, and corporate actions. Recent news highlighted Goldman Sachs raising its price target to $142 from $124 and analyst optimism around HOOD's expansion into crypto infrastructure, subscription services, and prediction markets; however, no specific catalyst tied to the price decline was identified.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Robinhood Markets earnings scheduled for 2026-11-04 (consensus EPS estimate $0.47) will provide concrete results against recent bullish positioning.
✓Sep 8 session - Last update: Sep 8, 2026, 4:50 PM ET
🛡Material / Earnings✓High confidence
What changed: Rigetti Computing, Inc. (RGTI) moved -3.53% from $16.39 to $15.81 on 2026-09-08, despite the company signing a definitive agreement with the U.S. Department of Commerce for a $100 million CHIPS Act award to accelerate superconducting quantum computer R&D. Under the terms, the U.S. government will receive a minority, non-controlling equity stake in the company. Volume was 3.5x the 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
RGTI earnings scheduled for 2026-11-09 (consensus EPS estimate: −$0.05).
✓Sep 8 session - Last update: Sep 8, 2026, 6:08 PM ET
🛡Material / Earnings✓High confidence
What changed: A. O. Smith Corporation (AOS) moved -2.55% from $60.36 to $58.82 on 2026-09-08. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
AOS earnings announcement on 2026-10-27 will be the next major data point to assess whether the recent pullback reflects forward guidance or consensus estimate concerns.
✓Sep 8 session - Last update: Sep 8, 2026, 5:09 PM ET
🛡Material / Earnings✓High confidence
What changed: Ingram Micro Holding Corporation (INGM) moved -2.67% from $29.16 to $28.38 on 2026-09-08. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move was not accompanied by unusual trading interest.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Ingram Micro Holding Corporation's earnings announcement on 2026-10-29.
✓Sep 8 session - Last update: Sep 8, 2026, 5:09 PM ET
🛡Material / Earnings✓High confidence
What changed: Bio-Rad Laboratories, Inc. (BIO) moved -2.72% from $390.73 to $380.12 on 2026-09-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The decline occurred on volume near its 5-day average, suggesting light trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor BIO's earnings announcement on 2026-10-29 for actual results versus the $2.23 consensus estimate.
✓Sep 8 session - Last update: Sep 8, 2026, 5:09 PM ET
🛡Material / Earnings✓High confidence
What changed: Lumen Technologies, Inc. (LUMN) moved -2.92% from $6.84 to $6.64 on 2026-09-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume traded near its 5-day average, indicating routine selling pressure rather than event-driven activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
LUMN earnings announcement on 2026-10-29 (date not yet confirmed) against consensus EPS estimate of −$0.13.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
HealthcareSeptember 8, 2026 · 9 min read
Amgen (AMGN) Falls as a Rival's Lp(a) Trial Failure Clouds Its Pipeline
Amgen fell about 8% to roughly $404 on September 8 even as it posted its own good news that morning — its cancer drug IMDELLTRA, with AstraZeneca's Imfinzi, hit its primary survival goal in a Phase III lung-cancer study. The shares dropped anyway, on a rival's failure: Novartis disclosed late last week that pelacarsen — its drug for lowering lipoprotein(a), or Lp(a), a genetic cardiovascular risk factor — failed the primary goal of its large Phase III outcomes trial, not reducing heart attacks, strokes and cardiovascular deaths despite lowering Lp(a). Because Amgen is racing in the same class with its own experimental drug, olpasiran, the read-through was direct: the first dedicated Phase III cardiovascular-outcomes readout of an Lp(a) therapy came up empty, casting doubt on the science behind the category. A separate same-day BMO Capital downgrade — on valuation and pipeline grounds — formed part of the negative backdrop. What cushioned the fall is that Amgen is a cheap, cash-rich defensive franchise — about 18 times forward earnings, a 2.5% dividend, ~$10 billion of free cash flow — so the Lp(a) opportunity was upside, not the foundation. Even so, the stock had run up ~43% over the year, and the Street was already cautious, with a large share of analysts at Hold and an average target below the pre-drop price.
AMGNRead →
TechnologySeptember 8, 2026 · 8 min read
Intel (INTC) Jumps on a High-NA EUV Milestone, Ahead of TSMC in Deployment
Intel rose about 8% to roughly $103 on September 8 after it and lithography partner ASML announced they have processed more than one million wafers using High-NA EUV — the newest, most advanced chipmaking lithography, by industry accounts more than any rival has run. Intel is deploying the technology on select layers of certain 18A products (chips such as Panther Lake), and reports throughput and yields meeting expectations, giving it a multi-year lead in High-NA production experience — TSMC is generally expected to bring High-NA into high-volume production around 2030, and Samsung targets it for DRAM around 2028. The milestone was the headline, though the stock also had a same-day analyst upgrade and reports of possible processor price increases. For a company whose whole case rests on rebuilding a credible foundry business, it was tangible proof the turnaround is producing real capability. The move caps a staggering ~322% one-year run — yet the fundamentals lag: Intel is still GAAP-unprofitable, and the Street stays cautious, with a Hold consensus (roughly two-thirds of covering analysts on the sidelines) and an average target only about 12% above the price. One firm (Northland) upgraded to Buy on the news; most are waiting for the manufacturing lead to become profit.
INTCRead →
TechnologySeptember 3, 2026 · 8 min read
Snowflake (SNOW) Jumps 16% on a Q2 Beat-and-Raise as a Software Pop Fades
Snowflake jumped as much as 26% intraday to a 52-week high of $384.56, then pared the gain to close up about 16.5% at $356.47, after reporting fiscal second-quarter results the evening before that beat and — the part that moves stocks — raised full-year guidance. Product revenue re-accelerated to about 37% growth ($1.49 billion), adjusted earnings of about $0.62 topped the ~$0.45 expected, and management lifted its full-year product-revenue target to roughly $6.07 billion while widening its margin outlook. The beat-and-raise sparked a sympathy surge across software — Datadog and MongoDB edged higher — on the idea that AI is a tailwind rather than a threat, but that broader enthusiasm largely faded by the close, leaving both peers up only about 2.5% while Snowflake held its gain. The catch is the price: after a ~55% year, Snowflake trades near 15 times forward sales and is still GAAP-unprofitable on heavy stock comp, though it closed somewhat below the average analyst target even after a wave of same-day target increases.
SNOWRead →
TechnologySeptember 1, 2026 · 8 min read
Apple (AAPL) Rises as Ternus Takes Over and the Sept. 9 iPhone Event Nears
Apple rose about 2.5% to roughly $325 on September 1, and the striking part was the company it kept: on a risk-off day driven by rising Treasury yields, Apple was one of the very few large-caps to rise — Meta also gained — while Microsoft, Nvidia and Alphabet slipped alongside the Nasdaq-100. The day carried two milestones. A long-planned leadership handover took effect: John Ternus, the hardware engineer behind the iPhone and Vision Pro, became CEO, with Tim Cook — chief executive since 2011 — moving to executive chairman; the succession was announced back in April, so this was the orderly handover, not fresh news. And Apple's September 9 event, expected to unveil the iPhone 18 Pro and a first foldable, is days away. The catch is valuation: at about 36 times earnings, after a ~40% run, the stock sits right at its average analyst target and about 6% below its late-July record — and the Street is split, with a Bernstein $370 bull case against a rare Jefferies bearish call (an Underperform near $264).
AAPLRead →
IndustrialsSeptember 1, 2026 · 8 min read
Deere (DE) Hits a Record High After a Baird Upgrade on a 2027 Ag Recovery
Deere rose about 2.6% to a record high near $676 on September 1, standing out on a day technology and semiconductors sold off. The catalyst was dated and company-specific: a day earlier, Baird's Mircea Dobre upgraded Deere to Outperform and raised his price target to $800 from $640, arguing North American crop economics improve in 2027 — corn back above breakeven, better soybean margins, tighter stocks-to-use. Baird upgraded AGCO the same day, and both farm-equipment makers rose while construction bellwether Caterpillar fell, isolating an agriculture-specific move rather than a broad machinery rally. The puzzle is the valuation: Deere trades at about 36 times trailing earnings, but that reflects an expected fiscal-2026 revenue trough (down ~10% on consensus estimates), with fiscal-2027 modeled up ~8% — the recovery the upgrade is betting on. The catch: after a ~40% run to a record, the Street is split, with 11 of 24 analysts at Hold and an average target just below the price.
DERead →
HealthcareSeptember 1, 2026 · 11 min read
McKesson (MCK) Rises as a Defensive Bid Meets a $2.25B Precision Medicine Deal
McKesson rose about 2.5% to near $907 (in the upper part of its 52-week range) on September 1, standing out as technology and semiconductors sold off. The move came amid a rotation away from technology and rate-sensitive growth, as defensive areas outperformed: with the Nasdaq-100 down more than 1%, low-beta healthcare gained, and the drug distributors were among the winners — Cardinal Health and Cencora also rose. McKesson had its own tailwinds, too. On August 25 it agreed to acquire Precision Medicine Group for about $2.25 billion, folding a clinical-research and commercialization business into its fast-growing Oncology & Multispecialty segment, and it paired that with a raised outlook and a 15% dividend increase — markers of a deliberate pivot from thin-margin drug distribution into higher-value oncology and specialty services. Even so, the stock trades at about 19 times forward earnings after growing EPS more than 50% over the past year. The catch: after a ~32% run, McKesson sits near the ~$987 average analyst target, so the valuation upside has narrowed. It is a high-quality, defensively-tilted compounder the market has already discovered.
MCKRead →